Adalimumab feasible for long-term control of hidradenitis suppurativa
Continuous weekly administration of adalimumab (ADA) at 40 mg appears to be an adequate option for long-term control of moderate-to-severe hidradenitis suppurativa (HS), a recent study has shown.
Eighty-eight study participants were given ADA (median age 35.5 years; 63.6 percent female) of whom 63 either achieved HS clinical response (HiSCR) at week 12 or showed a 25-percent reduction in abscess and inflammatory nodule (AN) counts relative to baseline (responders plus partial responders [PRR]; median age 36.0 years; 65.1 percent female).
Results were generally persistent over time. The percentage of ADA-treated patients achieving HiSCR increased from 52.3 percent at week 12 to 62.5 percent at week 36. By week 168, this proportion was back down to 52.3 percent.
Similarly, there were improvements persistent over time in the counts of AN, draining fistula, inflammatory nodules and total fistula in both groups. The same was true for pain rating. The rate of flare was low and stable.
There was also a meaningful improvement in Dermatology Life Quality Index scores in both groups, which was maintained through week 72.
In terms of treatment safety, no adverse events of opportunistic infections were seen, except for oral candidiasis, over the mean exposure duration of 2.21 and 2.26 patient-years in the ADA-treated and PRR groups, respectively. Three serious infections were reported overall, with one case of pneumonia being probably related to the treatment.
The most common treatment-emergent adverse events included hidradenitis, headaches, upper respiratory tract infections, arthralgia, diarrhoea and dizziness, among others.